A retrospective study from Yale School of Medicine shows association with overall survival in non-small cell lung cancer (NSCLC) patients treated with PD-1 pathway blockade using a panel of CD8, CD68, PD-L1 in a novel tissue-based multiplex assay
CAMBRIDGE, Mass, November 8, 2018 – Ultivue announced today that the Yale School of Medicine will present data highlighting the utility of a CD8, CD68, PD-L1 quantitative multiplex immunohistochemistry (IHC) panel. In this retrospective study conducted by the David Rimm Lab, the UltiMapper™ I/O PD-L1 research kit helped find preliminary associations of overall survival in a non-small cell lung cancer (NSCLC) patient cohort treated with PD-1 pathway blockade therapy.
"Quantitative multiplex IHC has proven its utility in the translational setting and is ready to be considered as a next-generation strategy of companion diagnostics for the adjuvant setting," said David Rimm, MD, PhD, Professor of Pathology and Medicine at Yale School of Medicine. "Using the UltiMapper™ I/O PD-L1 assay, our lab was able to assess the tumor micro-environment (TME) biological complexity and more accurately characterize de-identified patient samples that responded to PD-1 immunotherapy. We found that patients with high PD-L1 expression in macrophages experienced significantly longer overall survival. This retrospective data supported the use of more sophisticated biomarker quantification to identify NSCLC cancer patients that would benefit the most from cancer immunotherapy treatments," added Rimm.
In the study highlighted today, UltiMapper™ I/O PD-L1 research kits containing CD8, CD68, PD-L1, and pan-Cytokeratin markers, were used successfully to achieve exceptional multi-marker co-localization for improved cellular phenotyping.
“UltiMapper™ I/O research assays are based on our proprietary InSituPlex® DNA-barcoding technology allowing for the highest throughput of whole-slide, tissue biomarker spatial detection and analysis using instrumentation and software solutions currently found in the majority of immunohistochemistry laboratories,” said Louis Levy, Director of Corporate and Business Development. “Similar to the retrospective study conducted by the Rimm Lab, translational and clinical researchers are identifying multiple cell populations and functionally characterizing cell behavior within the tumor micro-environment using our growing portfolio of UltiMapper™ I/O assays,” Levy added.
Details of the poster, data, and times are as follows:
Saturday, November 10, 12:20 PM – 1:50 PM, 7 PM-8:30 PM
Biomarkers and Immune Monitoring
P116: Quantitative measurement of CD8, CD68 and PD-L1 expression in a novel multiplex assay and associations of overall survival in non-small cell lung cancer (NSCLC) patients treated with anti-PD-1 Therapy
Authors: Fahad S. Shabbir, Jon Zugazagoitia, Yuting Liu, Katir K. Patel, Brian S. Henick, Scott N. Gettinger, Roy S. Herbst, Kurt A. Schalper, David L. Rimm
By developing a single set of novel, proprietary reagents used both for biomarker discovery (higher content, low throughput) and translational use (lower content, high throughput), Ultivue is connecting the insights gained from research directly into the pathology lab. Ultivue’s UltiMapper™ multiplexed assays applied to tissue biopsy samples enable simultaneous quantitation of multiple biomarkers with sub-cellular spatial resolution and fit completely within traditional IHC workflows. Translational and clinical researchers leverage UltiMapper assays to elucidate complex biology and demonstrate their clinical utility as precision medicine research tools. Ultivue is expanding its UltiMapper assay product portfolio and menu of contract research services to provide a comprehensive set of precision medicine solutions for oncology research and focus in other therapeutic areas.
Ultivue is based in Cambridge, MA. For more information, visit www.ultivue.com
For Research Use Only. Not for use in diagnostic procedures.